The groundbreaking cancer research institute has just shared a major milestone in the fight against cancer. The first patient treated with their innovative cancer medicine AOH1996 is making positive progress.
City of hope has initiated a phase 1 clinical trail to evaluate the safety and efficiency of AOH1996 in patients with recurring solid tumours. This promising investigational pill has shown great potential in preclinical studies against various cancers, including breast, prostrate, brain, ovarian, cervical, skin, and lung cancers.
Dr. Linda Malkas has devoted two decades to developing AOH1996. This therapy is named after Anna Olivia Healey, AOH1996 uniquely targets cancer cells while sparing healthy ones, using a mechanism that disrupts cell replication and DNA repairs, ultimately leading to cancer cell death.
Imagine AOH1996 as a vigilant homeowner turning off the tap to prevent a bathtub from overflowing. Similarly AOH1996 halts cancers spread and eliminates it. Dr Malkas beautifully explains how this therapy is reshaping cancer treatment.
Dr. Vincent Chung, another key researcher, highlights how AOH1996's approach inhibits cancer cell growth by targetting a specific molecule crucial for their survival. This innovative strategy offers hope for patients whose cancers have resisted standard treatments.
The phase 1 trail, currently open at city of hope Los Angeles, aims to determine the optimal dosage and assess preliminary effectiveness of AOH1996. Eligible patients with solid tumors will take the medication twice daily, potentially opening new doors for those who have exhausted conventional options.
Source: 1) cityofhope.org
2) biotechbae